Physician profile
Scott Schafrank
NPI 1235120320
$7,506.19
in general payments reported to CMS, 2019-2025
36 companies · $1,099 in 2025
The $1,099 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,467 · 2020: $567 · 2021: $973 · 2022: $824 · 2023: $1,179 · 2024: $1,397 · 2025: $1,099.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,643 · Education: $31.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,642.78 |
| Education | $31.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,574.57 | 2019-2025 | Skyrizi, Rinvoq |
| Merz North America, INC. | $534.12 | 2019 | |
| Incyte Corporation | $466.32 | 2022-2024 | Opzelura |
| Ucb, INC. | $450.65 | 2021-2024 | Cimzia, Bimzelx |
| Regeneron Healthcare Solutions, INC. | $436.66 | 2021-2025 | Libtayo, Dupixent |
| Novartis Pharmaceuticals Corporation | $434.33 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $405.88 | 2020-2025 | Ilumya |
| Pfizer INC. | $382.32 | 2019-2024 | |
| Genzyme Corporation | $370.15 | 2019-2025 | |
| Lilly USA, LLC | $209.37 | 2019-2024 | Taltz, Olumiant, Zepbound |
| E.R. Squibb & Sons, L.L.C. | $192.24 | 2022-2025 | Sotyktu |
| Dermavant Sciences, INC. | $191.38 | 2023-2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $185.13 | 2019-2025 | Cabtreo, Arazlo, Jublia |
| Amgen INC. | $174.69 | 2023-2025 | Otezla, Otezla |
| Janssen Biotech, INC. | $143.51 | 2019-2025 | Tremfya |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $138.66 | 2024-2025 | |
| Celgene Corporation | $130.42 | 2019 | |
| Galderma Laboratories, L.P. | $113.11 | 2019-2025 | Nemluvio |
| Genentech USA, INC. | $101.04 | 2019-2024 | Erivedge |
| Leo Pharma INC. | $90.16 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $88.87 | 2019-2022 | |
| Lumenis, INC | $83.78 | 2021 | |
| Arcutis Biotherapeutics, INC. | $81.92 | 2024-2025 | Zoryve |
| Organon LLC | $78.90 | 2025 | Vtama, Nexplanon |
| Biofrontera INC. | $61.59 | 2023-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Verrica Pharmaceuticals INC. | $60.86 | 2023-2025 | Ycanth |
| Almirall LLC | $59.72 | 2019-2025 | Klisyri |
| Mission Pharmacal Company | $47.25 | 2019-2020 | |
| Kyowa Kirin, INC. | $41.66 | 2023-2024 | Poteligeo |
| Dermira, INC. | $35.63 | 2019-2020 | |
| Strata Skin Sciences, INC. | $32.46 | 2025 | Xtrac |
| Dusa Pharmaceuticals, INC. | $30.28 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $26.72 | 2019-2020 | |
| Conmed Corporation | $23.36 | 2023 | Visiclear |
| Journey Medical Corporation | $15.09 | 2023 | |
| Epi Health, LLC | $13.39 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Schafrank listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.